ArticleFrontiers in oncology2025
Vaginal lavage fluid can serve as a reliable method for early screening of endometrial cancer: a proof-of-concept study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endometrial cancer (EC) is one of the malignant tumors in the female reproductive system, and effective screening is urgently needed to reduce mortality. At present, the main screening method for endometrial cancer is ultrasound combined with curettage and pathological examination. We plan to explore a non-invasive, convenient, and low-cost new screening method for EC, providing a more convenient way for early screening of EC. Methods: We included a total of 11 patients with stage IA EC, and collected 8-10ml of blood, pathological paraffin sections, and vaginal lavage fluid for each patient. The collection of vaginal lavage fluid was performed before the patient's curettage or hysteroscopy for pathological examination. And perform high-throughput sequencing and further analysis on it. Results: In 11 cases with matched tumor and blood tissues, the extracted ctDNA concentration was significantly higher in vaginal lavage fluid than in plasma. The average and median MAF of different samples from paired tissue patients were significantly higher in vaginal lavage supernatant and sediment than in plasma. The types of genomic changes in the supernatant of vaginal lavage fluid are relatively consistent with those in the sediment and tumor tissue samples, but significantly different from those in the plasma. In addition, among the six most frequently mutated genes in this study, the consistency between vaginal lavage fluid supernatant and vaginal lavage fluid precipitation and tumor tissue genomic changes was significantly higher than in plasma. According to the results of 11 cases that provided tumor tissue samples, the genomic changes detected between the supernatant or precipitate of vaginal lavage fluid and tumor tissue were significantly consistent compared to those detected between tumor tissue and plasma. The potential targets for targeted treatment of endometrial cancer (KRAS, PIK3CA, MLH1, MSH6, POLE, PTEN) showed more significant changes in the supernatant of vaginal lavage fluid. Conclusion: The supernatant/precipitate of vaginal lavage fluid has significant clinical significance for early screening of endometrial cancer and may also have potential clinical value in guiding targeted therapy and evaluating prognosis. Vaginal lavage fluid gene sequencing may serve as a new method for initial screening of endometrial cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.